Lipid profile, low-density lipoprotein oxidation and ceruloplasmin in the progeny of families with a positive history of cardiovascular diseases and/or hyperlipidemia

Angiology

Volumn 60, Issue 4, 2009, Pages 455-461

  Makedou, Kali G ^a,e   Mikhailidis, Dimitri P ^c,d   Makedou, Areti ^b   Iliadis, Stavros ^e   Kourtis, Anargyros ^b   Vavatsi Christaki, Norma ^a   Papageorgiou, Georgios E ^e  

^a Medical School   (Greece)

^b University Hospital

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e NONE

Author keywords

Cardiovascular diseases; Ceruloplasmin; Children; Family history; LDL oxidation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; CERULOPLASMIN; CHOLESTEROL; COPPER; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; BIOLOGICAL MARKER; LIPID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CERULOPLASMIN BLOOD LEVEL; CHILD; CONTROLLED STUDY; FAMILY HISTORY; GREECE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; PROGENY; STATISTICAL ANALYSIS; ADULT; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PEDIGREE;

ADOLESCENT; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CERULOPLASMIN; CHILD; CHOLESTEROL, LDL; GENETIC PREDISPOSITION TO DISEASE; GREECE; HUMANS; HYPERLIPIDEMIAS; LIPID PEROXIDATION; LIPIDS; LIPOPROTEINS, LDL; MALONDIALDEHYDE; PEDIGREE; YOUNG ADULT;

EID: 70349573507     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319709338174     Document Type: Article

References (50)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J Am Med Assoc. 1984 ; 251 (3). 365-374.
2. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc. 1993 ; 269 (23). 3015-3023.
3. McGill HC Jr, McMahan CA, Zieske AW, et al, for the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Effect of nonlipid risk factors on atherosclerosis in youth with favorable lipoprotein profile. Circulation. 2001 ; 103: 1546-1550.
4. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. J Am Med Assoc. 1990 ; 264 (23). 318-324.
5. Weinstein DB, Carew TE, Steinberg D. Uptake and degradation of low density lipoprotein by swine arterial smooth muscle cells with inhibition of cholesterol biosynthesis. Biochem Biophys Acta. 1976 ; 424 (3). 404-421.
6. Goldstein JL, Ho YK, Basu SK, Brown MS Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA. 1979 ; 76 (1). 333-337.
7. Esterbauer H., Gebicki J., Puhl H., J?1/4rgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992 ; 13 (4). 341-390.
8. Steinbrecher UP, Parthasarathy S., Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA. 1984 ; 81 (12). 3883-3887.
9. Steinberg D., Parthasarathy S., Carew TE, Khoo JC, Witztum JL Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 ; 320 (14). 915-924.
10. Pitas RE Expression of the acetyl low density lipoprotein receptor by rabbit fibroblasts and smooth muscle cells. Up-regulation by phorbol esters. J Biol Chem. 1990 ; 265 (21). 12722-12727.
11. Steinberg D., Witztum JL Molecular Basis of Cardiovascular Disease. Philadelphia, PA: WB Saunders ; 1999: 458-475.
12. Osborn-Barnes HT, Akoh CC Effects of a-tocopherol, beta-carotene, and soy isoflavones on lipid oxidation of structured lipid-based emulsions. J Agric Food Chem. 2003 ; 51 (23). 6856-6860.
13. Siems W., Wiswedel I., Salerno C., et al. Beta-carotene breakdown products may impair mitochondrial functions-potential side effects of high dose beta-carotene supplementation. J Nutr Biochem. 2005 ; 16 (7). 385-397.
14. Galassetti P., Pontello A. Dietary effects on oxidation of low-density lipoprotein and atherogenesis. Curr Atheroscler Rep. 2006 ; 8 (6). 523-529.
15. Gimeno E., de la Torre-Carbot K., Lamuela-Raventos RM, et al. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A randomized crossover controlled trial. Br J Nutr. 2007 ; 98 (6). 1243-1250.
16. Rydén L. Ceruloplasmin. In: Lontie R, ed. Copper Proteins and Copper Enzymes, Volume III. Boca Raton, FL: CRC Press ; 1984: 37-100.
17. Saenko EL, Yaropolov AI, Harris ED Biological functions of ceruloplasmin expressed through copper-binding sites and a cellular receptor. J Trace Elem Exp Med. 1994 ; 7: 69-88.
18. Klebanoff SJ Bactericidal effect of Fe21, ceruloplasmin, and phosphate. Arch Biochem Biophys. 1992 ; 295 (2). 302-308.
19. Goldstein JM, Kaplan HB, Edelson HS, Weissmann G. Ceruloplasmin: scavenger of superoxide anion radicals. J Biol Chem. 1975 ; 254 (10). 4040-4045.
20. Ehrenwald E., Chisolm GM, Fox PL Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest. 1994 ; 93 (4). 1493-1501.
21. Salonen JT, Salonen R., Korpela H., Suntioinen S., Tuomilehto J. Serum copper and the risk of acute myocardial infarction: a prospective population study in men in Eastern Finland. Am J Epidemiol. 1991 ; 134 (3). 268-276.
22. Klipstein-Grobusch K., Grobbee DE, Koster JF, et al. Serum caeruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br J Nutr. 1999 ; 81 (2). 139-144. (Pubitemid 29103622)
23. National Cholesterol Education Program Report of the Expert panel on Blood Cholesterol levels in children and adolescents. Pediatrics. 1992 ; 89 (3 pt 2). 525-584.
24. Chung BH, Segrest JP, Ray MJ, et al. Single vertical spin density gradient ultracentrifugation. Methods Enzymol. 1986 ; 128: 181-209.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 ; 193 (1). 265-275.
26. Botsoglou NA, Fletouris DJ, Papgeorgiou GE, Vassilopoulos VN, Mantis AJ, Trakatellis AG Rapid, sensitive and specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food and feedstuff samples. J Agric Food Chem. 1994 ; 42 (9). 1931-1937.
27. Castelli WP Epidemiology of triglyceride: a review from Framingham. Am J Cardiol. 1992 ; 70: 3-9.
28. Assman G., Schulte H. Role of TG in coronary artery disease: lessons from the prospective cardiovascular Munster Study. Am J Cardiol. 1992 ; 70: 10-13.
29. Freedman DS, Srinivasan SR, Cresanta JL, Webber LS, Berenson GS Cardiovascular risk factors from birth to 7 years of age: the Bogalusa Heart Study. Serum lipids and lipoproteins. Pediatrics. 1987 ; 80 (5 pt 2). 789-796.
30. Kostner GM, Czinner A., Pfeiffer KH, Bihari-Varga M. Lipoprotein (a) concentrations as risk indicators for atherosclerosis. Arch Dis Child. 1991 ; 66 (9). 1054-1056.
31. Makedou A., Kourti M., Makedou K., Lazaridou S., Varlamis G. Lipid profile of children with family history of coronary heart disease or hyperlipidemia: 9-year experience of the Preventive Cardiovascular outpatient clinic. Angiology. 2005 ; 56 (4). 391-395.
32. Hickman TB, Briefel RR, Carroll MD, Rifkind BM, et al. Distributions and trends of serum lipid levels among United States Children and adolescents Ages 4-19 years: data from the third National Health and Nutrition Examination Survey. Prev Med. 1998 ; 27 (6). 879-890.
33. Davis PH, Dawson JD, Riley WA, Lauer RM Carotid intimalmedial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001 ; 104 (23). 2815-2819.
34. Bistritzer T., Rosenzweig L., Barr J., et al. Lipid profile with paternal history of coronary heart disease before age 40. Arch Dis Child. 1995 ; 73 (1). 62-65.
35. Terres W., Tatsis E., Pfalzer B., Beil FU, Beisiegel U., Hamm CW Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation. 1995 ; 91 (4). 948-950.
36. Maher VMG, Brown BG. Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol. 1995;6(4):229-235.
37. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein (a). JAMA. 1995;274(22):1771-1774.
38. US Preventive Services Task Force: Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007 ; 120 (1). e215-219.
39. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. ;. American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003 ; 107 (11). 1562-1566. (Pubitemid 36378499)
40. Parthasarathy S., Santanam N., Ramachandran S., Meilhac O. Oxidants and antioxidants in the atherogenesis: an appraisal. J Lipid Res. 1999 ; 40 (12). 2143-2147.
41. Regnstr?¶m J., Nilsson J., Tornvall P., Landou C., Hamsten A. Susceptibility of low density lipoprotein to oxidation and atherosclerosis. Lancet. 1992 ; 339 (8803). 883-887.
42. Makedou A., Makedou K., Papandreou D., et al. Dietary intervention in children with familial hypercholesterolemia. Clin Nutr. 2005 ; 24: 4, Suppl: LB012.
43. Enbergs A., Dorszewski A., Luft M., et al. Failure to confirm ferritin and caeruloplasmin as risk factors for the angiographic extent of coronary arteriosclerosis. Coron Artery Dis. 1998 ; 9 (2-3). 119-124.
44. Reunanen A., Knekt P., Aaran RK Serum ceruloplasmin level and the risk of myocardial infarction and stroke. Am J Epidemiol. 1992 ; 136 (9). 1082-1090.
45. Mänttäri M., Manninen V., Huttunen JK, et al. Serum ferritin and ceruloplasmin as coronary risk factors. Eur Heart J. 1994 ; 15 (12). 1599-1603.
46. Salonen JT, Salonen R., Seppänen K., Kantola M., Suntioinen S., Korpela H. Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. Br Med J. 1991 ; 302 (6779). 756-760.
47. Mezzetti A., Guglielmi MD, Pierdomenico SD, et al. Increased systemic oxidative stress after elective endarterectomy: relation to vascular healing and remodeling. Arterioscler Thromb Vasc Biol. 1999 ; 19 (11). 2659-2665.
48. Awadallah SM, Hamad M., Jbarah I., Salem NM, Mubarak MS Autoantibodies against oxidized LDL correlate with serum concentrations of ceruloplasmin in patients with cardiovascular disease. Clin Chim Acta. 2006 ; 365 (1-2). 330-336.
49. Ghayour-Mobarhan M., Lamb DJ, Taylor A., et al. Effect of statin therapy on serum trace element status in dyslipidaemic subjects. J Trace Elem Med Biol. 2005 ; 19 (1). 61-67.
50. Athyros VG, Kakafika AI, Tziomalos K., Karagiannis A., Mikhailidis DP Pleiotropic effects of statins-clinical evidence. Curr Pharm Des. 2009 ; 15 (5). 479-489.